Which is more profitable, Merck & or Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals keeps more of every sale as profit.

Which grows faster, Merck & or Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals grew its sales faster in recent years.

Which is cheaper, Merck & or Regeneron Pharmaceuticals?

Merck & costs less for each unit of yearly profit (lower P/E).

Which has less debt, Merck & or Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals would need fewer years of earnings to pay off its debt.

Merck &MRKvs

Regeneron PharmaceuticalsREGN

Merck & vs Regeneron Pharmaceuticals stock

Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.

In one sentence

Merck & is cheaper for its profits. Regeneron Pharmaceuticals is more profitable, grows faster and has less debt.

Side by side

	Merck &	Regeneron Pharmaceuticals
	$364 billion	$98.8 billion
	28.1%	31.4%
	+9.4%	+11.0%
	20.0×	21.9×
	1.2 years	Net cash
	17.8%	12.6%
	2.8%	0.5%

Open Merck &Open Regeneron Pharmaceuticals

How we compare

Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.

More comparisons: Merck & vs Roche · Merck & vs Sanofi · Merck & vs Stryker · Merck & vs Thermo Fisher Scientific · Regeneron Pharmaceuticals vs Roche · Regeneron Pharmaceuticals vs Thermo Fisher Scientific · Regeneron Pharmaceuticals vs UnitedHealth · Regeneron Pharmaceuticals vs AbbVie